TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Brief Summary: Compare the efficacy of ABT-874 versus etanercept in subjects with moderate to severe plaque psoriasis


Options:
A: Arm Label: Part 1 - Etanercept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept | Arm Label: Part 2 - Etanercept and nbUVB; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Device: nbUVB | Arm Label: Part 2 - Etanercept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Part 1 - Etanercept, Part 2 - Etanercept, Part 2 - Etanercept and nbUVB | Intervention Type: DEVICE; Name: nbUVB; Assigned to Arm(s): Part 2 - Etanercept and nbUVB
B: Arm Label: PF-06700841 Oral Solution/Suspension; Type: EXPERIMENTAL; Interventions: Drug: PF-06700841 oral solution/suspension | Arm Label: PF-06700841 Tablet; Type: EXPERIMENTAL; Interventions: Drug: PF-06700841 tablet | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: PF-06700841 oral solution/suspension; Assigned to Arm(s): PF-06700841 Oral Solution/Suspension | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: PF-06700841 tablet; Assigned to Arm(s): PF-06700841 Tablet
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Biological: ABT-874 | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Biological: etanercept | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: BIOLOGICAL; Name: ABT-874; Assigned to Arm(s): A | Intervention Type: BIOLOGICAL; Name: etanercept; Assigned to Arm(s): B | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): C
D: Arm Label: Secukinumab; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab | Arm Label: Ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab | Intervention Type: DRUG; Name: Secukinumab; Assigned to Arm(s): Secukinumab | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Ustekinumab

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Brief Summary: Compare the efficacy of ABT-874 versus etanercept in subjects with moderate to severe plaque psoriasis


Options:
A: Arm Label: Placebo/Adalimumab; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: Adalimumab | Arm Label: Adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo/Adalimumab | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Adalimumab, Placebo/Adalimumab
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Biological: ABT-874 | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Biological: etanercept | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: BIOLOGICAL; Name: ABT-874; Assigned to Arm(s): A | Intervention Type: BIOLOGICAL; Name: etanercept; Assigned to Arm(s): B | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): C
C: Arm Label: Active Treatment 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Active Treatment 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Treatment; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment 10 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment 5 mg BID | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment
D: Arm Label: Etanercept 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Etanercept | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Etanercept 50 mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Study for Prostate Cancer, Randomizing Between Two Radiation Dose Levels (68 Gy vs. 78 Gy) and Utilizing Three Dimensional Conformal Radiotherapy
Brief Summary: 3-D conformal radiotherapy offers the opportunity to reach higher tumor doses with acceptable complication rates compared to conventional radiotherapy. There are retrospective and preliminary prospective reports of a better local control / disease free survival (including PSA control) using higher tumor doses. A prospective randomised phase III study is required to validate these reports. The purpose of this randomized phase III study is to investigate and compare the tumor control and toxicity in prostate cancer patients treated to 68 Gy and 78 Gy;


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Radiation: Radiotherapy 70 Gy, Drug: Androgen blockade | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Radiation: Radiotherapy 76 Gy, Drug: Androgen blockade | Arm Label: Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Radiotherapy 76 Gy | Intervention Type: RADIATION; Name: Radiotherapy 70 Gy; Assigned to Arm(s): Arm 1 | Intervention Type: RADIATION; Name: Radiotherapy 76 Gy; Assigned to Arm(s): Arm 2, Arm 3 | Intervention Type: DRUG; Name: Androgen blockade; Assigned to Arm(s): Arm 1, Arm 2
B: Arm Label: Radical prostatectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Radical prostatectomy | Arm Label: Conformal radiation therapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Conformal radiation therapy | Arm Label: Active monitoring; Type: ACTIVE_COMPARATOR; Interventions: Other: Active monitoring | Intervention Type: PROCEDURE; Name: Radical prostatectomy; Assigned to Arm(s): Radical prostatectomy | Intervention Type: RADIATION; Name: Conformal radiation therapy; Assigned to Arm(s): Conformal radiation therapy | Intervention Type: OTHER; Name: Active monitoring; Assigned to Arm(s): Active monitoring
C: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Radiation: 3-dimensional conformal radiation therapy, Radiation: intensity-modulated radiation therapy | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Radiation: 3-dimensional conformal radiation therapy, Radiation: intensity-modulated radiation therapy | Intervention Type: RADIATION; Name: 3-dimensional conformal radiation therapy; Assigned to Arm(s): Arm I, Arm II | Intervention Type: RADIATION; Name: intensity-modulated radiation therapy; Assigned to Arm(s): Arm I, Arm II
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Gray | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Radiation: Gray | Intervention Type: RADIATION; Name: Gray; Assigned to Arm(s): 1 | Intervention Type: RADIATION; Name: Gray; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Approaches to Correcting Vitamin D Inadequacy and Maintaining Adequacy
Brief Summary: Vitamin D is available in two forms, vitamin D2 and vitamin D3. It has previously been assumed that these two forms maintain blood vitamin D equally. However, this may not be the case. This study will evaluate whether D2 and D3 produce equal elevation of blood vitamin D. Additionally, it will evaluate whether once per month vitamin D dosing is as effective in maintaining blood vitamin D levels as daily dosing.


Options:
A: Arm Label: vitamin D2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: vitamin D2 | Arm Label: vitamin D3; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: vitamin D2; Assigned to Arm(s): vitamin D2 | Intervention Type: DIETARY_SUPPLEMENT; Name: vitamin D3; Assigned to Arm(s): vitamin D3
B: Arm Label: Lite OJ with Ca and VitD; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Reduced energy (lite) OJ fortified with Calcium and Vitamin D, Behavioral: Nutrition Counseling | Arm Label: Lite OJ without Ca and VitD; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Nutrition Counseling, Dietary Supplement: Reduced energy (lite) OJ without Calcium and Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Reduced energy (lite) OJ fortified with Calcium and Vitamin D; Assigned to Arm(s): Lite OJ with Ca and VitD | Intervention Type: BEHAVIORAL; Name: Nutrition Counseling; Assigned to Arm(s): Lite OJ with Ca and VitD, Lite OJ without Ca and VitD | Intervention Type: DIETARY_SUPPLEMENT; Name: Reduced energy (lite) OJ without Calcium and Vitamin D; Assigned to Arm(s): Lite OJ without Ca and VitD
C: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: Control; Type: OTHER; Interventions: Dietary Supplement: Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Treatment | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Control
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Ergocalciferol (vitamin D2), Dietary Supplement: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Ergocalciferol (vitamin D2), Dietary Supplement: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Cholecalciferol (vitamin D3), Dietary Supplement: Placebo | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Cholecalciferol (vitamin D3), Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol (vitamin D3); Assigned to Arm(s): 3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Ergocalciferol (vitamin D2); Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Ergocalciferol (vitamin D2); Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol (vitamin D3); Assigned to Arm(s): 4 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 1, 2, 3, 4

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Family Based Intervention for Adolescent Suicide Attempters
Brief Summary: This study will evaluate the effectiveness of an individually tailored suicide prevention treatment program called SAFETY in reducing suicide and suicide attempts in adolescents.


Options:
A: Arm Label: Case management; Type: EXPERIMENTAL; Interventions: Behavioral: Case management | Arm Label: Enhanced usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Enhanced usual care | Intervention Type: BEHAVIORAL; Name: Case management; Assigned to Arm(s): Case management | Intervention Type: OTHER; Name: Enhanced usual care; Assigned to Arm(s): Enhanced usual care
B: Arm Label: SAFETY I; Type: EXPERIMENTAL; Interventions: Behavioral: SAFETY | Arm Label: SAFETY II; Type: EXPERIMENTAL; Interventions: Behavioral: SAFETY | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced usual care | Intervention Type: BEHAVIORAL; Name: SAFETY; Assigned to Arm(s): SAFETY I, SAFETY II | Intervention Type: BEHAVIORAL; Name: Enhanced usual care; Assigned to Arm(s): Control
C: Arm Label: Telephone-based management; Type: EXPERIMENTAL; Interventions: Behavioral: Treatment as Usual | Arm Label: iFightDepression for Suicide; Type: EXPERIMENTAL; Interventions: Behavioral: Treatment as Usual | Arm Label: Treatment as Usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Telephone-based management, Behavioral: iFightDepression for Suicide | Arm Label: Self Awareness of Mental Health; Type: EXPERIMENTAL; Interventions: Behavioral: Treatment as Usual, Behavioral: Self Awareness of Mental Health | Intervention Type: BEHAVIORAL; Name: Telephone-based management; Assigned to Arm(s): Treatment as Usual | Intervention Type: BEHAVIORAL; Name: iFightDepression for Suicide; Assigned to Arm(s): Treatment as Usual | Intervention Type: BEHAVIORAL; Name: Treatment as Usual; Assigned to Arm(s): Self Awareness of Mental Health, Telephone-based management, iFightDepression for Suicide | Intervention Type: BEHAVIORAL; Name: Self Awareness of Mental Health; Assigned to Arm(s): Self Awareness of Mental Health
D: Arm Label: COPESS and Treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Other: COPESS | Arm Label: Treatment as usual only; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: COPESS; Assigned to Arm(s): COPESS and Treatment as usual

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pain, Sexual Dysfunction and Depression in Hemodialysis Patients
Brief Summary: This study is seeking to identify the most effective strategy to manage pain, sexual dysfunction, and depression in patients receiving chronic hemodialysis therapy.


Options:
A: Arm Label: Standard; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard | Arm Label: Decision Support & Navigation; Type: EXPERIMENTAL; Interventions: Behavioral: Decision Support & Navigation | Intervention Type: BEHAVIORAL; Name: Decision Support & Navigation; Assigned to Arm(s): Decision Support & Navigation | Intervention Type: BEHAVIORAL; Name: Standard; Assigned to Arm(s): Standard
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: dietary education | Intervention Type: BEHAVIORAL; Name: dietary education; Assigned to Arm(s): A
C: Arm Label: SCT-based behavioral intervention; Type: EXPERIMENTAL; Interventions: Behavioral: SCT-based behavioral intervention | Arm Label: Attention control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Attention Control | Intervention Type: BEHAVIORAL; Name: SCT-based behavioral intervention; Assigned to Arm(s): SCT-based behavioral intervention | Intervention Type: BEHAVIORAL; Name: Attention Control; Assigned to Arm(s): Attention control
D: Arm Label: Symptom management nurse intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Symptom management nurse intervention | Arm Label: Feedback intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Feedback intervention | Intervention Type: BEHAVIORAL; Name: Symptom management nurse intervention; Assigned to Arm(s): Symptom management nurse intervention | Intervention Type: BEHAVIORAL; Name: Feedback intervention; Assigned to Arm(s): Feedback intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pain, Sexual Dysfunction and Depression in Hemodialysis Patients
Brief Summary: This study is seeking to identify the most effective strategy to manage pain, sexual dysfunction, and depression in patients receiving chronic hemodialysis therapy.


Options:
A: Arm Label: Group Based; Type: EXPERIMENTAL; Interventions: Behavioral: Group-Based (GB) Intervention | Arm Label: Home-Based; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Home-Based (HB) Intervention | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Group-Based (GB) Intervention; Assigned to Arm(s): Group Based | Intervention Type: BEHAVIORAL; Name: Home-Based (HB) Intervention; Assigned to Arm(s): Home-Based
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: dietary education | Intervention Type: BEHAVIORAL; Name: dietary education; Assigned to Arm(s): A
C: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Contract | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Behavioral Contract; Assigned to Arm(s): Intervention Group
D: Arm Label: Symptom management nurse intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Symptom management nurse intervention | Arm Label: Feedback intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Feedback intervention | Intervention Type: BEHAVIORAL; Name: Symptom management nurse intervention; Assigned to Arm(s): Symptom management nurse intervention | Intervention Type: BEHAVIORAL; Name: Feedback intervention; Assigned to Arm(s): Feedback intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diet Composition - Metabolic Regulation and Long-term Compliance
Brief Summary: This study will compare a high-protein/low-carbohydrate diet (modified paleolithic diet, MPD) with a diet high in slow carbohydrates (Nordic Nutrition Recommendations, NNR). The diets will be compared with respect effects on weight reduction, metabolic regulation, and long-term compliance to the diet regimes. Seventy-two postmenopausal overweight healthy women have been recruited and will be followed for two years.

The following variables will be studied:

* Anthropometry
* DEXA
* OGTT
* Liver fat content measured with 1H-MRS
* Hepatic 11β-HSD1 activity, measured with cortisone/cortisol conversion test


Options:
A: Intervention Type: OTHER; Name: Fructose; Assigned to Arm(s): N/A
B: Arm Label: Sucrose Sweetened Beverage; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Beverage | Arm Label: Aspartame Sweetened Beverage; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Beverage | Arm Label: Saccharin Sweetened Beverage; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Beverage | Arm Label: Sucralose Sweetened Beverage; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Beverage | Arm Label: Rebaudioside A Sweeteened Beverage; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Beverage | Intervention Type: DIETARY_SUPPLEMENT; Name: Beverage; Assigned to Arm(s): Aspartame Sweetened Beverage, Rebaudioside A Sweeteened Beverage, Saccharin Sweetened Beverage, Sucralose Sweetened Beverage, Sucrose Sweetened Beverage
C: Arm Label: Low carbohydrate diet (F); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Low carbohydrate - high fat diet | Arm Label: Traditional diet (K); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: High carbohydrate - low fat diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Low carbohydrate - high fat diet; Assigned to Arm(s): Low carbohydrate diet (F) | Intervention Type: DIETARY_SUPPLEMENT; Name: High carbohydrate - low fat diet; Assigned to Arm(s): Traditional diet (K)
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: NNR (Nordic Nutrition Recommendations) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: MPD (Modified paleolithic diet) | Intervention Type: BEHAVIORAL; Name: NNR (Nordic Nutrition Recommendations); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: MPD (Modified paleolithic diet); Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diet Composition - Metabolic Regulation and Long-term Compliance
Brief Summary: This study will compare a high-protein/low-carbohydrate diet (modified paleolithic diet, MPD) with a diet high in slow carbohydrates (Nordic Nutrition Recommendations, NNR). The diets will be compared with respect effects on weight reduction, metabolic regulation, and long-term compliance to the diet regimes. Seventy-two postmenopausal overweight healthy women have been recruited and will be followed for two years.

The following variables will be studied:

* Anthropometry
* DEXA
* OGTT
* Liver fat content measured with 1H-MRS
* Hepatic 11β-HSD1 activity, measured with cortisone/cortisol conversion test


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: NNR (Nordic Nutrition Recommendations) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: MPD (Modified paleolithic diet) | Intervention Type: BEHAVIORAL; Name: NNR (Nordic Nutrition Recommendations); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: MPD (Modified paleolithic diet); Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: dietary intervention; Assigned to Arm(s): N/A
D: Arm Label: low-fat diet; Type: EXPERIMENTAL; Interventions: Behavioral: low-fat diet | Arm Label: moderate-fat diet; Type: EXPERIMENTAL; Interventions: Behavioral: moderate-fat diet | Arm Label: high-fat diet; Type: EXPERIMENTAL; Interventions: Behavioral: high-fat diet | Intervention Type: BEHAVIORAL; Name: low-fat diet; Assigned to Arm(s): low-fat diet | Intervention Type: BEHAVIORAL; Name: moderate-fat diet; Assigned to Arm(s): moderate-fat diet | Intervention Type: BEHAVIORAL; Name: high-fat diet; Assigned to Arm(s): high-fat diet

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Personal Patient Profile Prostate (P4) Randomized, Multisite Trial
Brief Summary: The purpose of this study is to determine whether or not participation in an experimental program called the "P4 program" is useful to men who are faced with choices about treatment for their early stage prostate cancer. The P4 program consists of a series of questions and information for the participant.

Before seeing the cancer specialist, participants will answer several questionnaires on a computer. This will take about 20-30 minutes. Participants may choose to do this on a computer at home or on a touch-screen computer in the clinic. Half the participants will then be shown several highly rated informational websites about prostate cancer treatments. The other half, based on the individual participant's answers, will receive the P4 program's customized written and on-screen information. Reading the information and watching videos will take about 20 minutes.

About one month later, and again 6 months, participants will complete follow-up questionnaires electronically or by mail. These questionnaires will help us understand how each participant's decision for treatment of their prostate cancer went. Answering these questionnaires should take about 20 minutes each time.


Options:
A: Arm Label: Decision Aid; Type: EXPERIMENTAL; Interventions: Other: Decision Aid | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Decision Aid; Assigned to Arm(s): Decision Aid
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Osteoporosis Choice Decision Aid | Arm Label: Arm 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Osteoporosis Choice Decision Aid; Assigned to Arm(s): Arm 1
C: Intervention Type: DEVICE; Name: Heart-to-Heart Decision Aid; Assigned to Arm(s): N/A
D: Arm Label: P4; Type: EXPERIMENTAL; Interventions: Behavioral: P4 | Arm Label: Usual care+; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: P4; Assigned to Arm(s): P4

Answer: D